Management of Vasculitis in Primary Sjögren’s Syndrome

Severity Assessment

The European League Against Rheumatism (EULAR) recommends using the ESSDAI scoring system to stratify disease activity in primary Sjögren’s syndrome–associated vasculitis【1】【2】.
For moderate activity (ESSDAI 5–13), initiate glucocorticoids at 0.5–1 mg/kg/day of prednisone‑equivalent【1】.
High activity (ESSDAI ≥ 14) or any organ‑threatening manifestation warrants combination therapy with high‑dose glucocorticoids plus an immunosuppressive agent【1】【3】.

Glucocorticoids: Prednisolone 1 mg/kg/day (maximum 60 mg/day); methylprednisolone pulses may be used for severe presentations【1】【4】.
Immunosuppressive agents: Choice is guided by the organ(s) involved; no head‑to‑head trials exist, so selection is individualized【3】【2】.
- Cyclophosphamide (0.5 g IV every 15 days, up to 6 pulses) is recommended for life‑threatening disease manifestations【4】.
- Mycophenolate mofetil or azathioprine are appropriate for less severe but organ‑threatening vasculitis【3】.
- Methotrexate may be used in early systemic disease without organ‑threatening features【5】.

Severe presentations—including diffuse cutaneous vasculitis with ulceration, rapidly progressive glomerulonephritis or renal failure, cryoglobulinemic multineuritis with marked motor deficit, cerebral vasculitis with focal deficits, and severe hemolytic anemia or thrombocytopenia—require immediate high‑dose glucocorticoids combined with cyclophosphamide【1】.
The recommended regimen mirrors protocols for ANCA‑associated vasculitis: cyclophosphamide 2 mg/kg/day orally (max 200 mg/day) or IV pulses of 0.5 g every 15 days, together with prednisolone 1 mg/kg/day【5】【6】.

Rituximab (1 g IV every 15 days × 2) is advised for severe, refractory systemic vasculitis, especially cryoglobulinemic vasculitis and vasculitis associated with MALT lymphoma【4】.
- Over 400 patients with primary Sjögren’s syndrome have received rituximab in published series, demonstrating reductions in ESSDAI scores and glucocorticoid requirements【4】.
In patients who fail rituximab, belimumab (10 mg/kg at weeks 0, 2, 4 then every 4 weeks) achieved clinical response in approximately 60 % of cases【4】.
Abatacept may be considered based on limited open‑label evidence【4】.

Therapeutic success is defined as a reduction of ≥ 3 points in the global ESSDAI score【1】.
Regular ESSDAI reassessment is recommended to guide ongoing treatment adjustments【1】.

Immunosuppressive monotherapy without concurrent glucocorticoids is not supported; > 95 % of reported cases used glucocorticoids alongside immunosuppressants【3】【2】.

After remission, taper glucocorticoids to the lowest effective dose, recognizing that some patients may require prolonged low‑dose therapy for severe organ involvement【1】【3】.
Continue immunosuppressive agents as glucocorticoid‑sparing therapy, balancing efficacy against potential adverse effects【3】【2】.
No fixed duration for maintenance therapy is established; clinicians should follow maintenance strategies used for other systemic autoimmune diseases【3】.

Obtain baseline chest radiography and complete pulmonary function tests (PFTs) even in asymptomatic patients to identify subclinical interstitial lung disease, which occurs frequently in this population, as recommended by the European League Against Rheumatism (EULAR) 7, 8
Perform high-resolution CT (HRCT) if respiratory symptoms present or PFTs abnormal, according to the American Thoracic Society (ATS) guidelines 7, 8
Assess for systemic involvement using EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) to quantify disease severity and guide treatment intensity, as suggested by the EULAR 7, 9

Repeat PFTs every 6-12 months to track disease trajectory in patients with baseline abnormalities or respiratory symptoms, as recommended by the ATS 7, 8
Evaluate for treatable causes of chronic cough, including gastroesophageal reflux, postnasal drip, and asthma, before attributing to xerotrachea, according to the ATS guidelines 8

Monitor for lymphadenopathy, fevers, and night sweats at each visit, as 2-5% develop lymphoma, as recommended by the European League Against Rheumatism (EULAR) 7, 10

Consider hydroxychloroquine for fatigue and arthralgias in patients with low disease activity (ESSDAI 1-4), as suggested by the American College of Rheumatology (ACR) 9, 10
Manage sicca symptoms with topical therapies, such as artificial tears and saliva substitutes, as recommended by the ACR 7, 11
Initiate glucocorticoids at minimum effective dose (typically 0.5 mg/kg prednisone equivalent) for moderate disease activity (ESSDAI 5-13), as suggested by the EULAR 9, 10

First-line treatment for interstitial lung disease is mycophenolate mofetil or azathioprine plus moderate-dose corticosteroids, as recommended by the EULAR 9
Add nintedanib as second-line maintenance for progressive fibrotic ILD, according to the EULAR guidelines 9

Define therapeutic response as ≥3 point reduction in global ESSDAI score, as suggested by the EULAR 9, 10
Reassess ESSDAI at regular intervals to guide treatment adjustments, as recommended by the EULAR 7, 9